Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase

por Hompesch, Marcus, Muchmore, Douglas B., Morrow, Linda, Vaughn, Daniel E.
Publicado 2011

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

por Morrow, Linda, Muchmore, Douglas B., Hompesch, Marcus, Ludington, Elizabeth A., Vaughn, Daniel E.
Publicado 2013

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study

por Hompesch, Marcus, Kang, Jahoon, Han, OakPil, Trautmann, Michael E, Sorli, Christopher H, Ogbaa, Ike, Stewart, John, Morrow, Linda
Publicado 2021

Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

por Sha, Sue, Devineni, Damayanthi, Ghosh, Atalanta, Polidori, David, Hompesch, Marcus, Arnolds, Sabine, Morrow, Linda, Spitzer, Heike, Demarest, Keith, Rothenberg, Paul
Publicado 2014

OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

por Powell, David, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo
Publicado 2019

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

por Powell, David R, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo
Publicado 2019

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

por Rosenstock, Julio, Bergenstal, Richard M., Blevins, Thomas C., Morrow, Linda A., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado 2013

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subj...

por Crutchlow, Michael F., Palcza, John S., Mostoller, Kate M., Mahon, Chantal D., Barbour, April M., Marcos, Michael C., Xu, Yang, Watkins, Elaine, Morrow, Linda, Hompesch, Marcus
Publicado 2017

Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies

por Nunez, Derek J., Bush, Mark A., Collins, David A., McMullen, Susan L., Gillmor, Dawn, Apseloff, Glen, Atiee, George, Corsino, Leonor, Morrow, Linda, Feldman, Paul L.
Publicado 2014

BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in...

por Frias, Juan Pablo, Lawitz, Eric J, Ortiz-LaSanta, Grisell, Franey, Bridgette, Morrow, Linda, Chen, Chao-Yin, Tseng, Leo, Charlton, R William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit
Publicado 2021

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers

por Toledo, Frederico G. S., Martin, William F., Morrow, Linda, Beysen, Carine, Bajorunas, Daiva, Jiang, Ying, Silverman, Bernard L., McDonnell, David, Namchuk, Mark N., Newcomer, John W., Graham, Christine
Publicado 2021

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

por de la Peña, Amparo, Riddle, Matthew, Morrow, Linda A., Jiang, Honghua H., Linnebjerg, Helle, Scott, Adam, Win, Khin M., Hompesch, Marcus, Mace, Kenneth F., Jacobson, Jennie G., Jackson, Jeffrey A.
Publicado 2011

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two e...

por Beysen, Carine, Schroeder, Patricia, Wu, Eric, Brevard, Julie, Ribadeneira, Maria, Lu, Wei, Dole, Kiran, O'Reilly, Terry, Morrow, Linda, Hompesch, Marcus, Hellerstein, Marc K., Li, Kelvin, Johansson, Lars, Kelly, Patrick F.
Publicado 2020

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

por DeFronzo, Ralph A., Hompesch, Marcus, Kasichayanula, Sreeneeranj, Liu, Xiaoni, Hong, Ying, Pfister, Marc, Morrow, Linda A., Leslie, Bruce R., Boulton, David W., Ching, Agatha, LaCreta, Frank P., Griffen, Steven C.
Publicado 2013

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

por Baruch, Amos, Wong, Chin, Chinn, Leslie W., Vaze, Anjali, Sonoda, Junichiro, Gelzleichter, Thomas, Chen, Shan, Lewin-Koh, Nicholas, Morrow, Linda, Dheerendra, Suresh, Boismenu, Richard, Gutierrez, Johnny, Wakshull, Eric, Wilson, Maria E., Arora, Puneet S.
Publicado 2020

Exploring the insulin secretory properties of the PGD(2)-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients

por Skrtic, Stanko, Tyrberg, Björn, Broberg, Malin, Ericsson, Hans, Schnecke, Volker, Kjaer, Magnus, Hompesch, Marcus, Andersson, Eva-Marie, Ryberg, Erik, Aivazidis, Alexander, Wennberg Huldt, Charlotte, Löfgren, Lars, Morrow, Linda, Parkinson, Joanna, Rydén-Bergsten, Tina, Watkins, Elaine, Sörhede Winzell, Maria
Publicado 2018

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

por Hanrahan, John P., Seferovic, Jelena P., Wakefield, James D., Wilson, Phebe J., Chickering, Jennifer G., Jung, Joon, Carlson, Kenneth E., Zimmer, Daniel P., Frelinger, Andrew L., Michelson, Alan D., Morrow, Linda, Hall, Michael, Currie, Mark G., Milne, G. Todd, Profy, Albert T.
Publicado 2019